InsidersTradesSigma
Nykode Therapeutics ASA Stock: price and management transactions · Norway · Oslo Børs
Follow the Nykode Therapeutics ASA stock price and the full insider trade history of the company, a listed equity based in Norway. Shares are quoted on NO NO, under the supervision of Oslo Børs. Operating in the Health Care sector, Nykode Therapeutics ASA has logged 52 public disclosures. The latest transaction was filed on 30 January 2026 (Option grant). Among the most active insiders: Unknown insider (NYKD). All data is free.
52
Insider Decl.
0
Thresholds
€47m
25 ops.
Buy Volume
€23m
9 ops.
Sell Volume
10Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 30 January 2026
Declarations52 total
600,000 shares@ NOK 7.17920.6% of flowOptionXOSLOSLO:664566
46,356 shares@ NOK 2.1621.2% of flowShareXOSLOSLO:660428
Ideal exit: 21 Aug 2026 (T+270)
280,000 shares@ NOK 1.8113100.0% of flowShareXOSLOSLO:657002
Ideal exit: 7 Jul 2026 (T+270)
55,944 shares@ NOK 1.7921.5% of flowShareXOSLOSLO:656985
Ideal exit: 7 Jul 2026 (T+270)
3,000,000 shares@ NOK 2.138840.2% of flowShareXOSLOSLO:642414
Ideal exit: 22 Dec 2025 (T+270)
100,000 shares@ NOK 3.001.8% of flowShareXOSLOSLO:635453
Ideal exit: 16 Sept 2025 (T+270)
5,000,000 shares@ NOK 1.917258.0% of flowShareXOSLOSLO:631746
Ideal exit: 5 Aug 2025 (T+270)
50,000 shares@ NOK 5.6514.0% of flowShareXOSLOSLO:625848
Ideal exit: 18 May 2025 (T+270)
65,000 shares@ NOK 16.22670.2% of flowOptionXOSLOSLO:619739
25,000 shares@ NOK 14.9749.8% of flowShareXOSLOSLO:614682
Ideal exit: 21 Dec 2024 (T+270)
20,311 shares@ NOK 15.276100.0% of flowShareXOSLOSLO:614248
Ideal exit: 16 Dec 2024 (T+270)
10,000 shares@ NOK 14.0029.5% of flowShareXOSLOSLO:613304
Ideal exit: 8 Dec 2024 (T+270)
25,000 shares@ NOK 14.8150.2% of flowShareXOSLOSLO:613028
Ideal exit: 3 Dec 2024 (T+270)
40,000 shares@ NOK 13.8128.1% of flowShareXOSLOSLO:612998
Ideal exit: 3 Dec 2024 (T+270)
20,000 shares@ NOK 16.5970.5% of flowShareXOSLOSLO:612556
Ideal exit: 29 Nov 2024 (T+270)
6,000 shares@ NOK 16.7121.8% of flowShareXOSLOSLO:612321
Ideal exit: 25 Nov 2024 (T+270)
@ €0.7486OptionXOSLOSLO:604960
9,850 shares@ NOK 17.1035.5% of flowShareXOSLOSLO:602645
Ideal exit: 27 Jul 2024 (T+270)
20,000 shares@ NOK 16.3616.1% of flowShareXOSLOSLO:602442
Ideal exit: 23 Jul 2024 (T+270)
450,000 shares@ NOK 18.0244100.0% of flowShareXOSLOSLO:602118
Ideal exit: 21 Jul 2024 (T+270)
500,000 shares@ NOK 17.82100.0% of flowShareXOSLOSLO:602096
Ideal exit: 21 Jul 2024 (T+270)
ShareXOSLOSLO:602015
25 of 52 declarations
About Nykode Therapeutics ASA
Nykode Therapeutics ASA is a biopharmaceutical company focused on developing immunotherapies for the treatment of cancer and infectious diseases. It is listed on the XOSL market.
